Literature DB >> 11138328

Interleukin-1 cluster and tumor necrosis factor-alpha gene polymorphisms in polymyalgia rheumatica.

L Boiardi1, C Salvarani, J M Timms, T Silvestri, P L Macchioni, F S di Giovine.   

Abstract

OBJECTIVE: To investigate whether polymorphisms in the interleukin (IL)-1 locus (human chrom. 2q13) and TNF-alpha gene are associated with susceptibility to or severity of polymyalgia rheumatica (PMR).
METHODS: The study included 92 consecutive PMR patients diagnosed over a 5-year period who were prospectively followed-up for at least one year and 79 healthy controls over the age of 50 residing in the same area. All the patients and controls were Caucasians of Italian origin. We tested the allelic distribution of IL-1A (+4845), IL-B (-511), IL-B (+3954), IL-1RN Intron 2 VNTR and TNFA (-308). Frequencies were compared in the patient and control groups.
RESULTS: A statistically significant association between PMR patients and the IL1RN*2 allele in the homozygous state was found [OR 8.46 (95% CI 1.05-68.31)]. The polymorphisms in the other genes of the IL-1 gene cluster did not reveal any association with PMR when compared with controls. A weak association between PMR patients and the TNF2 allele was also present [OR 2.09 (95% CI 1.0-4.17)]. None of the gene variants studied was associated with the disease severity of PMR.
CONCLUSION: Our findings show that IL1RN*2 allele, particularly in the homozygous state, is associated with susceptibility to, but not with the severity of, PMR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138328

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.

Authors:  Normann Steiner; Georg Göbel; Daniela Michaeler; Anna-Luise Platz; Wolfgang Prokop; Anna Maria Wolf; Dominik Wolf; Christina Duftner; Eberhard Gunsilius
Journal:  Blood Adv       Date:  2021-03-23

2.  Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis.

Authors:  M Cutolo; C M Montecucco; L Cavagna; R Caporali; S Capellino; P Montagna; L Fazzuoli; B Villaggio; B Seriolo; A Sulli
Journal:  Ann Rheum Dis       Date:  2006-04-27       Impact factor: 19.103

Review 3.  Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis.

Authors:  Alberto Floris; Matteo Piga; Elisabetta Chessa; Mattia Congia; Gian Luca Erre; Maria Maddalena Angioni; Alessandro Mathieu; Alberto Cauli
Journal:  Clin Rheumatol       Date:  2021-08-20       Impact factor: 3.650

Review 4.  Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica.

Authors:  M A Gonzalez-Gay
Journal:  Arthritis Res       Date:  2001-02-26

5.  Contribution of single nucleotide polymorphisms of the IL1A gene to the cleavage of precursor IL-1alpha and its transcription activity.

Authors:  Yasushi Kawaguchi; Akiko Tochimoto; Masako Hara; Manabu Kawamoto; Tomoko Sugiura; Seiji Saito; Naoyuki Kamatani
Journal:  Immunogenetics       Date:  2007-04-18       Impact factor: 3.330

6.  The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future Scenarios.

Authors:  Ciro Manzo; Elvis Hysa; Alberto Castagna; Marco Isetta
Journal:  J Pers Med       Date:  2022-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.